Fosun Pharma, officially known as Shanghai Fosun Pharmaceutical (Group) Co., Ltd., is a leading global healthcare company headquartered in China. Established in 1994, the firm has expanded its operations across major regions, including Asia, Europe, and North America, positioning itself as a key player in the pharmaceutical and healthcare industry. Fosun Pharma focuses on research and development, manufacturing, and distribution of innovative medicines, vaccines, and medical devices. Its core products, which include a diverse range of therapeutic solutions, are distinguished by their commitment to quality and efficacy. The company has achieved significant milestones, including strategic partnerships and acquisitions that enhance its market presence. With a strong emphasis on innovation and a robust pipeline, Fosun Pharma continues to solidify its position as a prominent force in the global healthcare landscape.
How does Fosun Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Fosun Pharma's score of 53 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Fosun Pharma reported total carbon emissions of approximately 929,435,000 kg CO2e, comprising 184,016,000 kg CO2e from Scope 1, 653,644,000 kg CO2e from Scope 2, and 91,775,000 kg CO2e from Scope 3. This marked a slight decrease from 2023, where total emissions were about 960,864,000 kg CO2e, with Scope 1 at 210,819,000 kg CO2e, Scope 2 at 677,874,000 kg CO2e, and Scope 3 at 72,171,000 kg CO2e. Fosun Pharma has set ambitious reduction targets, aiming for a 10% reduction in comprehensive energy consumption intensity by 2025 compared to 2020 levels, which translates to 2.287 GJ/RMB 10,000 revenue. Additionally, the company targets a 15% reduction in carbon emission intensity for Scope 2 by 2025, aiming for 0.23 tons/RMB 10,000 revenue. The company is also committed to achieving net zero emissions by 2050, as proposed by the International Energy Agency. This long-term goal encompasses all scopes of emissions, reflecting a comprehensive approach to climate action. Fosun Pharma's emissions data is sourced from its parent company, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., ensuring a consistent and transparent reporting framework.
Access structured emissions data, company-specific emission factors, and source documents
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|
Scope 1 | 288,447,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 457,732,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | 0,000,000 | 000,000 | 0,000,000 | 000,000 | 000,000 | 00,000,000 | 00,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fosun Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.